These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 29044941)

  • 21. The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients.
    Yu P; Zhou M; Qu J; Fu L; Li X; Cai R; Jin B; Teng Y; Liu J; Shi J; Zhang J
    BMC Cancer; 2018 Nov; 18(1):1076. PubMed ID: 30404612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of a systemic inflammatory response in patients undergoing multimodality therapy for advanced colorectal cancer.
    Inoue Y; Iwata T; Okugawa Y; Kawamoto A; Hiro J; Toiyama Y; Tanaka K; Uchida K; Mohri Y; Miki C; Kusunoki M
    Oncology; 2013; 84(2):100-7. PubMed ID: 23147449
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer.
    Cho KM; Park H; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
    Oncotarget; 2017 Jan; 8(2):2329-2341. PubMed ID: 27911876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain.
    Martínez-Lago N; Fernández-Montes A; Covela M; Brozos EM; De la Cámara J; Méndez Méndez JC; Jorge-Fernández M; Cousillas Castiñeiras A; Reboredo C; Arias Ron D; Pellón Augusto ML; González Villarroel P; Graña B; Salgado Fernández M; Carral Maseda A; Vázquez Rivera F; Candamio Folgar S; Reboredo López M;
    BMC Cancer; 2021 Jan; 21(1):64. PubMed ID: 33446148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Palliative primary tumor resection provides survival benefits for the patients with metastatic colorectal cancer and low circulating levels of dehydrogenase and carcinoembryonic antigen.
    He WZ; Rong YM; Jiang C; Liao FX; Yin CX; Guo GF; Qiu HJ; Zhang B; Xia LP
    Chin J Cancer; 2016 Jun; 35(1):58. PubMed ID: 27357402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer.
    Sunakawa Y; Tsuji A; Denda T; Segawa Y; Negoro Y; Shimada K; Kochi M; Nakamura M; Kotaka M; Tanioka H; Takagane A; Tani S; Yamaguchi T; Watanabe T; Takeuchi M; Fujii M; Ichikawa W
    Target Oncol; 2017 Dec; 12(6):787-794. PubMed ID: 29064002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of predictive markers for patients with advanced colorectal cancer.
    Byström P; Berglund Å; Nygren P; Wernroth L; Johansson B; Larsson A; Glimelius B
    Acta Oncol; 2012 Sep; 51(7):849-59. PubMed ID: 22974092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis.
    Li MX; Liu XM; Zhang XF; Zhang JF; Wang WL; Zhu Y; Dong J; Cheng JW; Liu ZW; Ma L; Lv Y
    Int J Cancer; 2014 May; 134(10):2403-13. PubMed ID: 24122750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inflammation-based prognostic scores as indicators to select candidates for primary site resection followed by multimodal therapy among colorectal cancer patients with multiple metastases.
    Shimura T; Toiyama Y; Saigusa S; Imaoka H; Okigami M; Fujikawa H; Hiro J; Kobayashi M; Ohi M; Araki T; Inoue Y; Uchida K; Mohri Y; Kusunoki M
    Int J Clin Oncol; 2017 Aug; 22(4):758-766. PubMed ID: 28299463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome.
    Thomsen M; Skovlund E; Sorbye H; Bolstad N; Nustad KJ; Glimelius B; Pfeiffer P; Kure EH; Johansen JS; Tveit KM; Christoffersen T; Guren TK
    Br J Cancer; 2018 Jun; 118(12):1609-1616. PubMed ID: 29872151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical validity of tissue carcinoembryonic antigen expression as ancillary to serum carcinoembryonic antigen concentration in patients curatively resected for colorectal cancer.
    Park JW; Chang HJ; Kim BC; Yeo HY; Kim DY
    Colorectal Dis; 2013 Sep; 15(9):e503-11. PubMed ID: 23711333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer.
    Prager GW; Braemswig KH; Martel A; Unseld M; Heinze G; Brodowicz T; Scheithauer W; Kornek G; Zielinski CC
    Cancer Sci; 2014 Aug; 105(8):996-1001. PubMed ID: 24850362
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early changes in carcinoembryonic antigen but not in calcitonin levels are correlated with the progression-free survival in medullary thyroid carcinoma patients treated with cytotoxic chemotherapy.
    Hajje G; Borget I; Leboulleux S; Chougnet C; Al Ghuzlan A; Mirghani H; Caramella C; Hartl D; Schlumberger M; Baudin E
    Eur J Endocrinol; 2013 Feb; 168(2):113-8. PubMed ID: 23093698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
    Yao Y; Yuan D; Liu H; Gu X; Song Y
    Cancer Immunol Immunother; 2013 Mar; 62(3):471-9. PubMed ID: 22986452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial.
    Yoshino T; Obermannová R; Bodoky G; Garcia-Carbonero R; Ciuleanu T; Portnoy DC; Kim TW; Hsu Y; Ferry D; Nasroulah F; Tabernero J
    Eur J Cancer; 2017 Jun; 78():61-69. PubMed ID: 28412590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are Markers of Systemic Inflammation Good Prognostic Indicators in Colorectal Cancer?
    Rossi S; Basso M; Strippoli A; Schinzari G; D'Argento E; Larocca M; Cassano A; Barone C
    Clin Colorectal Cancer; 2017 Dec; 16(4):264-274. PubMed ID: 28412137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer.
    Chua W; Charles KA; Baracos VE; Clarke SJ
    Br J Cancer; 2011 Apr; 104(8):1288-95. PubMed ID: 21448173
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prognostic role of baseline CEA and CA 19-9 values and their time-dependent variations in advanced colorectal cancer patients submitted to first-line therapy.
    Tampellini M; Ottone A; Alabiso I; Baratelli C; Forti L; Berruti A; Aroasio E; Scagliotti GV
    Tumour Biol; 2015 Mar; 36(3):1519-27. PubMed ID: 25374062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concordance of Carcinoembryonic Antigen Ratio and Response Evaluation Criteria in Solid Tumors as Prognostic Surrogate Indicators of Metastatic Colorectal Cancer Patients Treated with Chemotherapy.
    Huang SC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Lin CC; Jiang JK; Chang SC
    Ann Surg Oncol; 2015 Jul; 22(7):2262-8. PubMed ID: 25586242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy.
    Strimpakos AS; Cunningham D; Mikropoulos C; Petkar I; Barbachano Y; Chau I
    Ann Oncol; 2010 May; 21(5):1013-9. PubMed ID: 19861580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.